Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Paul Harker-Murray, Thierry Leblanc, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugieres, Kara M. Kelly, Peter D. Cole, Richard A. Drachtman, Faith Galderisi, Mariana Sacchi, Ying-Ming Jou, Stephen Daw
Institutions: Children's Hospital of Wisconsin, Assistance Publique – Hôpitaux de Paris, Hôpital Robert-Debré, Centro di Riferimento Oncologico, Justus-Liebig-Universität Gießen, Martin Luther University Halle-Wittenberg, Hôpital de la Timone, Johns Hopkins Hospital, Princess Máxima Center, Seattle Children's Hospital, Istituto Giannina Gaslini, Santobono Children's Hospital, Institut Gustave Roussy, Roswell Park Comprehensive Cancer Center, Rutgers Cancer Institute, Seagen (United States), Bristol-Myers Squibb (United States), University College Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2899309317